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Alzheimer’s disease (AD) is a common,
progressive degeneration of human brain
structure and function, resulting in a dete-
rioration of mood, behavior, functional
ability, cognition, andmemory (Alzheimer
et al., 1995). Globally, 5 million new
cases of AD are diagnosed annually, with
one new AD case being reported every
7 s (Alzheimer Association, 2012). In this
country taking care of AD patients places
a tremendous socioeconomic burden not
only on unpaid caregivers but on our
health care system as a whole. The neu-
ropathology of AD is highly variable
and complex in its presentation, and the
greatest risk factor for AD is age.
Besides the appearance of neurofibril-
lary tangles, at the root of the AD problem
appears to be an up-regulation in the
generation of small, toxic, and highly amy-
loidogenic 42 amino acid amyloid beta
(Aβ42) peptides that self-associate, ulti-
mately clumping into pro-inflammatory
and microglia-activating senile plaques
(SP). Interestingly, all of the enzymatic
machinery responsible for the generation
of Aβ42, and subsequent SP formation,
are plasma membrane-resident secre-
tases or modifier/accelerator proteins that
are involved in the catabolic processing
of the membrane-bound beta-amyloid
precursor protein (βAPP). Besides the
secretases, these modifier/accelerator
accessory proteins include nicastrin,
APH-1, presenilin-1, presenilin-2, sor-
tilin, the TSPAN membrane proteins, and
others; Table 1). Interestingly, dietary and
systemic factors such as cholesterol, which
perturb the biophysical structure of the
phospholipid membrane and reorganize
lipid raft domains where βAPP process-
ing appears to occur, further contributes,
via protein-lipid and protein-protein
interactions, to membrane-mediated
dysfunction of homeostatic βAPP neu-
robiology (Hicks et al., 2012; Kania et al.,
2012). Indeed lipid raft nanodomains,
of which there are millions in a single
cell, have recently gained considerable
attention as these membrane-embedded
clusters of phospholipid-, sphingolipid-
and cholesterol-enriched, integral and
peripheral membrane proteins (such as
the β- and γ-secretases) are instrumental
in the processing of βAPP holoprotein
and hence the amyloidogenic process
itself (Hicks et al., 2012; Kania et al.,
2012; Kosicek and Hecimovic, 2013;
Table 1).
Membrane-integral or membrane-
peripheral associated modulators of Aβ42
peptide generation such as TSPAN12 or
sortilin further contribute to the kinetics
of formation, cleavage, processing, and
speciation of βAPP (Lukiw, 2012a,b,c;
Pallesen and Vaegter, 2012; Table 1).
More recently, the participation of a
membrane-spanning triggering receptor
expressed in myeloid cells 2 (TREM2)
protein supports a role for yet another
plasma membrane-integral glycopro-
tein in phagocytosis and the clearance
of Aβ42 peptides before they aggre-
gate into SP (Niemitz, 2012; Singaraja,
2013). Of further interest is that plasma
membrane-derived phospholipids and
esterified dococahexaenoic acid (DHA)
are the substrate for phospholipases, and
hence the precursors for arachidonic acid
cycle metabolites and cyclooxygenase
conversion, that supports inflammatory
signaling in the CNS (Heneka et al.,
2010). Plasma membranes can also pro-
vide free DHA for conversion via a
15-lipoxygenase (15-LOX) into neuropro-
tectin D1 (NPD1), a potent neurotrophic
docosanoid (Lukiw and Bazan, 2010).
Hence, depending on the processing
pathways and biological signals utilized,
the plasma membrane can be the source of
both beneficial and detrimental signals to
further modulate amyloidogenic, inflam-
matory or neurotrophic aspects of the AD
process.
Lastly, plasma membrane-derived exo-
somes are 30–90 nm diameter vesicles
secreted into the extracellular milieu
(Alexandrov et al., 2012; Lukiw et al.,
2012; Fais et al., 2013). Besides contain-
ing various proteins and molecular con-
stituents reflective of their cells of ori-
gin, these vesicles contain microRNAs
as their most abundant nucleic acids
(Alexandrov et al., 2012; Lukiw, 2012c).
It is intriguing that these plasma mem-
brane derived organelles may be capa-
ble of the paracrine transfer of genetic
information between cells, either within
the local environment of the brain or
throughout the entire cerebrospinal or
systemic circulation (Kania et al., 2012;
Lukiw, 2012b,c; Lukiw et al., 2012; Fais
et al., 2013). As exosome formation and
release is mediated by the plasma mem-
brane it is interesting to speculate that the
microRNA-mediated transfer of genetic
material between cells of the CNS and
the intercellular transport of microRNA
may actually be at least in part depen-
dent on plasma membrane-mediated bio-
logical mechanisms. Again, environmen-
tal and dietary factors which modu-
late plasma membrane integrity, flexibil-
ity and lipid raft effects might not only
be relevant in amyloidogenesis but also
in paracrine microRNA trafficking and
the intercellular spreading of these soluble
and mobile genetic signals. Such activities
may have profound importance in both
health and disease. For example, plasma
membrane biophysics, dynamics, and lipid
raft domain perturbation by cholesterol
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Plasma membrane association Function/dysfunction References
βAPP Integral Intercellular signaling; source of all
Aβ peptides and peptide fragments;
unknown functions.






Hicks et al., 2012; Lukiw, 2012a,b,c;
Kosicek and Hecimovic, 2013
β-secretase Peripheral Amyloidogenic βAPP processing Hicks et al., 2012; Lukiw, 2012a,b,c;
Kosicek and Hecimovic, 2013
γ-secretase Integral Amyloidogenic βAPP processing Hicks et al., 2012; Lukiw, 2012a,b,c;
Kosicek and Hecimovic, 2013
TSPAN Integral Promote non-amyloidogenic βAPP
processing
Xu et al., 2009; Lukiw et al., 2012
TREM2 Integral Innate immune surveillance;
phagocytosis?
Niemitz, 2012; Singaraja, 2013
Exosomes Plasma membrane derived Paracrine communication; AD
spreading (?); intercellular transport
of genetic material (?)
Alexandrov et al., 2012; Lukiw et al.,
2012; Fais et al., 2013
Lipid rafts A dedicated “nanoregion” of the
plasma membrane intrinsic to amyloid
processing and amyloiogenesis
Cholesterol and other dietary lipids
appear to modulate the processing
of βAPP and amyloidogenesis
Hicks et al., 2012; Kania et al., 2012;
Lukiw, 2012a,b,c; Orth and Bellosta,
2012; Kosicek and Hecimovic, 2013
and the HMG-CoA reductase inhibitors
known as statins which target choles-
terol metabolism, for example, might not
only have effects on cholesterol incorpo-
ration into membranes and lipid raft for-
mation but also in exocytosis and the
potential of intercellular transfer of genetic
information between cells (Hicks et al.,
2012; Kania et al., 2012; Lukiw, 2012a,b,c;
Fais et al., 2013; Kosicek and Hecimovic,
2013).
The interactions amongst these biolog-
ical players with the plasma membrane
remains poorly understood and require
additional study. To cite just one fur-
ther example is the potential involvement
of neurotropic viral infection with AD,
involving processes that are plasma
membrane-mediated, pro-inflammatory,
and evasive of the brain’s innate immune
response (Lukiw and Bazan, 2010; Ball
et al., 2012). The papers provided in
the current “Frontiers Physiology” issue
entitled “Membrane alterations and
Alzheimer’s disease” should certainly
shed some light on these recently recog-
nized plasma-membrane mediated events
and how they impact both AD initiation
and proliferation, and the AD process
itself. Identifying their mechanisms,
how they work and interact should
yield a multitude of novel therapeutic
strategies and targets that have not yet
been considered for the clinical manage-
ment of this tragic human neurological
disorder.
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